Cargando…
Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108878/ http://dx.doi.org/10.1186/1479-5876-12-S1-P5 |
| _version_ | 1782327802730643456 |
|---|---|
| author | Kefford, Richard Sullivan, Ryan J Miller, Wilson H Elez, Elena M Tan, Daniel Kim, Kevin B Long, Georgina V Flaherty, Keith T Tai, David Stutvoet, Simone Maacke, Heiko Whiley, Matt Parseval, Laure Moutouh-de Tabernero, Josep |
| author_facet | Kefford, Richard Sullivan, Ryan J Miller, Wilson H Elez, Elena M Tan, Daniel Kim, Kevin B Long, Georgina V Flaherty, Keith T Tai, David Stutvoet, Simone Maacke, Heiko Whiley, Matt Parseval, Laure Moutouh-de Tabernero, Josep |
| author_sort | Kefford, Richard |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4108878 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-41088782014-08-04 Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results Kefford, Richard Sullivan, Ryan J Miller, Wilson H Elez, Elena M Tan, Daniel Kim, Kevin B Long, Georgina V Flaherty, Keith T Tai, David Stutvoet, Simone Maacke, Heiko Whiley, Matt Parseval, Laure Moutouh-de Tabernero, Josep J Transl Med Poster Presentation BioMed Central 2014-05-06 /pmc/articles/PMC4108878/ http://dx.doi.org/10.1186/1479-5876-12-S1-P5 Text en Copyright © 2014 Kefford et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Kefford, Richard Sullivan, Ryan J Miller, Wilson H Elez, Elena M Tan, Daniel Kim, Kevin B Long, Georgina V Flaherty, Keith T Tai, David Stutvoet, Simone Maacke, Heiko Whiley, Matt Parseval, Laure Moutouh-de Tabernero, Josep Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results |
| title | Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results |
| title_full | Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results |
| title_fullStr | Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results |
| title_full_unstemmed | Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results |
| title_short | Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results |
| title_sort | phase ib/ii, open-label, dose-escalation study of lgx818, an oral selective braf inhibitor, in combination with mek162, an oral mek1/2 inhibitor, in patients with braf v600-dependent advanced solid tumors: preliminary results |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108878/ http://dx.doi.org/10.1186/1479-5876-12-S1-P5 |
| work_keys_str_mv | AT keffordrichard phaseibiiopenlabeldoseescalationstudyoflgx818anoralselectivebrafinhibitorincombinationwithmek162anoralmek12inhibitorinpatientswithbrafv600dependentadvancedsolidtumorspreliminaryresults AT sullivanryanj phaseibiiopenlabeldoseescalationstudyoflgx818anoralselectivebrafinhibitorincombinationwithmek162anoralmek12inhibitorinpatientswithbrafv600dependentadvancedsolidtumorspreliminaryresults AT millerwilsonh phaseibiiopenlabeldoseescalationstudyoflgx818anoralselectivebrafinhibitorincombinationwithmek162anoralmek12inhibitorinpatientswithbrafv600dependentadvancedsolidtumorspreliminaryresults AT elezelenam phaseibiiopenlabeldoseescalationstudyoflgx818anoralselectivebrafinhibitorincombinationwithmek162anoralmek12inhibitorinpatientswithbrafv600dependentadvancedsolidtumorspreliminaryresults AT tandaniel phaseibiiopenlabeldoseescalationstudyoflgx818anoralselectivebrafinhibitorincombinationwithmek162anoralmek12inhibitorinpatientswithbrafv600dependentadvancedsolidtumorspreliminaryresults AT kimkevinb phaseibiiopenlabeldoseescalationstudyoflgx818anoralselectivebrafinhibitorincombinationwithmek162anoralmek12inhibitorinpatientswithbrafv600dependentadvancedsolidtumorspreliminaryresults AT longgeorginav phaseibiiopenlabeldoseescalationstudyoflgx818anoralselectivebrafinhibitorincombinationwithmek162anoralmek12inhibitorinpatientswithbrafv600dependentadvancedsolidtumorspreliminaryresults AT flahertykeitht phaseibiiopenlabeldoseescalationstudyoflgx818anoralselectivebrafinhibitorincombinationwithmek162anoralmek12inhibitorinpatientswithbrafv600dependentadvancedsolidtumorspreliminaryresults AT taidavid phaseibiiopenlabeldoseescalationstudyoflgx818anoralselectivebrafinhibitorincombinationwithmek162anoralmek12inhibitorinpatientswithbrafv600dependentadvancedsolidtumorspreliminaryresults AT stutvoetsimone phaseibiiopenlabeldoseescalationstudyoflgx818anoralselectivebrafinhibitorincombinationwithmek162anoralmek12inhibitorinpatientswithbrafv600dependentadvancedsolidtumorspreliminaryresults AT maackeheiko phaseibiiopenlabeldoseescalationstudyoflgx818anoralselectivebrafinhibitorincombinationwithmek162anoralmek12inhibitorinpatientswithbrafv600dependentadvancedsolidtumorspreliminaryresults AT whileymatt phaseibiiopenlabeldoseescalationstudyoflgx818anoralselectivebrafinhibitorincombinationwithmek162anoralmek12inhibitorinpatientswithbrafv600dependentadvancedsolidtumorspreliminaryresults AT parsevallauremoutouhde phaseibiiopenlabeldoseescalationstudyoflgx818anoralselectivebrafinhibitorincombinationwithmek162anoralmek12inhibitorinpatientswithbrafv600dependentadvancedsolidtumorspreliminaryresults AT tabernerojosep phaseibiiopenlabeldoseescalationstudyoflgx818anoralselectivebrafinhibitorincombinationwithmek162anoralmek12inhibitorinpatientswithbrafv600dependentadvancedsolidtumorspreliminaryresults |